Colorectal Cancer - Shaping the future dynamics of colorectal cancer management

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.

Biotech in the New EU Member States: Policy Recommendations

The study carried-out on the development status and capacity of healthcare biotechnology in the new EU Member States and candidate countries shows a much contrasted picture of biotechnology development in this region. Each country has a different economic development strategy and a unique history and capacity in the life-science and healthcare sector which determines its path to development. Based on these observations, it would be unsuitable to propose general recommendations in a sort of unique formula to build or develop a healthy healthcare biotechnology sector.

Donwnload free 14 pages report at our Download Section.

Biotech in the New EU Member States: an Emerging Sector

This report is the first of its kind to try and understand the state of the biotechnology industry in the new Member States and candidate countries. As with any bottom-up work, it took a lot of effort and persistence to gather data on current and prospective developments in this area. Our goal was to strengthen the understanding of the European biotechnology scene and we believe that with the knowledge accumulated we have reached this goal. This report should enable policy makers and investors to make informed decisions about biotechnology support and development. The databases developed during this project will also provide better international visibility to the companies, which could lead to new cooperation or investment.

Donwnload free 33 pages report at our Download Section.

Community Antibacterials - Pipelines wither as generic tidal wave takes its toll

Datamonitor research points to this sector, beleaguered by patent expiries, barriers to market entry and uptake, becoming increasingly inclement towards branded drugs. Generic incursion has taken a heavy toll on the market at a number of levels. The volume of key brands facing generic competition makes it even harder for remaining products to court large revenues in the community sector.

Molecular systems to open new markets

As a result of the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens, there is a need for novel antigen delivery technologies to improve vaccine efficacy and safety. This report assesses key strategies, technologies and products for vaccine antigen delivery. It provides an overview of opportunities and challenges for the sector and a future outlook.

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Osteoporosis - Novel agents to battle for payer acceptance

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.

Acute Leukemias - Persistent unmet needs confer significant commercial opportunity

While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.

Chronic Leukemias - Is there room left for improvement?

CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.

Genzyme Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector.

The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis

This report provides comprehensive coverage of every class of drugs across major cardiovascular indications and profiles the underlying trends and factors driving the market. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period.

Diabetes to the fore as generics hit primary care markets

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.

Commercial strategies in cardiovascular and metabolic diseases-successful market positioning at company and brand level becomes paramount

Datamonitor expects commercial strategies in the cardiovascular and metabolic markets to become increasingly important as the markets mature. The report details strategies used by pharmaceutical companies to capture market share, to differentiate brands from the competition, for revenue maximization and for the defense of brand revenues from generic competition.

Technology Transfer Strategies: Maximizing the returns from new technologies

Technology transfer is a long-established part of early-stage research within the pharmaceutical and biotechnology industries. Although technology transfer offices have traditionally been associated with inefficiency and a lack of commercial judgment, recent trends have shown improvements in staffing, expertise and service levels.

Evolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors

‘Evolving Trends in Biopharmaceutical Licensing' is a report published by Business Insights that provides a detailed analysis of licensing strategies in the biopharmaceutical industry over the 2001-08 period. This report examines the growth of the biopharmaceutical industry, deal-making trend data, drivers and challenges facing biopharmaceutical licensing, and profiles of biopharmaceutical licensing among leading companies.

The Autoimmune Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Autoimmune disorders have been one of the most prominent growth segments in the pharma industry over the last decade. A growing patient population and high levels of unmet need are the main drivers of market growth, and novel biologics are increasingly helping to fulfill patient need, with their high cost helping to drive market sales.

The Top 10 Contract Research Organizations:Positioning, performance and SWOT analyses

Cost containment and regulatory pressures within the pharma industry are driving R&D outsourcing across the globe. Clinical obstacles to approval have become more significant due to the growing availability of existing generic treatments, and the trend to adopt Health Economics Outcomes Research (HEOR) assessments is increasing the complexity of clinical research.

Market developments, outsourcing hotspots and growth strategies

This report aims to identify the hotspots and profile the leading players in the global pharmaceutical contract manufacturing market.